INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 166 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $382,554 | +43.3% | 28,485 | +47.2% | 0.00% | 0.0% |
| Q2 2022 | $267,000 | -31.2% | 19,355 | -18.9% | 0.00% | 0.0% |
| Q1 2022 | $388,000 | -74.5% | 23,855 | -61.3% | 0.00% | -85.7% |
| Q4 2020 | $1,524,000 | -69.3% | 61,718 | -48.4% | 0.01% | -65.0% |
| Q3 2020 | $4,963,000 | -20.4% | 119,697 | -8.0% | 0.02% | -35.5% |
| Q2 2020 | $6,235,000 | +293.9% | 130,138 | +918.8% | 0.03% | +520.0% |
| Q4 2019 | $1,583,000 | -33.2% | 12,774 | -64.2% | 0.01% | -44.4% |
| Q3 2019 | $2,368,000 | +314.0% | 35,688 | +396.2% | 0.01% | +350.0% |
| Q2 2019 | $572,000 | -67.9% | 7,192 | -54.8% | 0.00% | -71.4% |
| Q1 2019 | $1,781,000 | +271.0% | 15,927 | +234.5% | 0.01% | +250.0% |
| Q4 2018 | $480,000 | -12.4% | 4,762 | +9.8% | 0.00% | 0.0% |
| Q3 2018 | $548,000 | +29.9% | 4,338 | -13.7% | 0.00% | 0.0% |
| Q2 2018 | $422,000 | +29.4% | 5,024 | -5.2% | 0.00% | +100.0% |
| Q1 2018 | $326,000 | – | 5,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |